Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs (GUARDIANLUNG)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04930289 |
Recruitment Status :
Enrolling by invitation
First Posted : June 18, 2021
Last Update Posted : August 10, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Interstitial Lung Disease COPD Cystic Fibrosis Pulmonary Fibrosis Pulmonary Arterial Hypertension Emphysema | Device: LungGuard |
GUARDIAN-Lung is a post-market, observational registry of adult and pediatric lung transplant recipient patients whose donor lungs was preserved and transported within the LUNGguard. The data is being collected retrospectively from medical records of patients already transplanted before the initiation of the registry and any new patients who meet the eligibility criteria.
About 500 male and female subjects (including pediatric patients) meeting the study inclusion and exclusion criteria will be enrolled into the study at about 5 clinical sites.
Candidates that fit the eligibility criteria and have had their donor lungs transported with a Paragonix product or a standard of care method can be enrolled. The baseline characteristics and outcomes of the two groups will be compared.
Study Type : | Observational [Patient Registry] |
Estimated Enrollment : | 500 participants |
Observational Model: | Cohort |
Time Perspective: | Cross-Sectional |
Target Follow-Up Duration: | 1 Year |
Official Title: | Global Utilization and Registry Database for Improved Preservation of Donor Lungs |
Actual Study Start Date : | October 15, 2021 |
Estimated Primary Completion Date : | June 15, 2023 |
Estimated Study Completion Date : | December 30, 2023 |

Group/Cohort | Intervention/treatment |
---|---|
LungGuard patients
Patients whose donor lung(s) was transported with the LungGuard device.
|
Device: LungGuard
The LUNGguard is an FDA cleared and is a CE-marked medical device intended to be used for the static hypothermic preservation of lungs during transportation and eventual transplantation into a recipient using cold storage solutions indicated for use with the lungs. The intended organ storage time for the LUNGguard is up to 8 hours. |
Standard Transport Patients
Patients whose donor lung(s) was transported with a method other than the LungGuard
|
- Number of subjects with Primary Graft Dysfunction (PGD) [ Time Frame: Post-transplant through 1 year post ]The number of subjects that develop PGD after transplant
- Number of subjects with rejection [ Time Frame: Post-transplant through 1 year post ]Subjects that show signs to rejection after transplant
- Survival [ Time Frame: Post-transplant through 1 year post ]patient survival post-transplant
- ICU Length of Stay [ Time Frame: Transplant through 1 year post-transplant ]Days the subject spent the ICU post-transplant
- Hospital Length of Stay [ Time Frame: Transplant through 1 year post-transplant ]Days the subject was in the hospital in total after transplant
- Number of rehospitalizations [ Time Frame: post-transplant through 1 year ]The number of times the subject was readmitted to the hospital after discharged post-transplant
- How long subjects needed mechanical support [ Time Frame: pre-transplant through 48 hours post-transplant ]Amount of time (minutes) mechanical support (EMCO and ventilator) was needed pre and post transplant

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Donor and donor lungs matched to the prospective recipient based upon institutional medical practice
- Registered male or female primary lung transplant candidates including pediatric candidates
Exclusion Criteria:
- Donor and donor lungs that do not meet institutional clinical requirements for transplantation
- Patients who are incarcerated persons (prisoners)
- Patients who have had a previous major organ transplant (heart, lungs, liver, kidney, pancreas)
- Patients who are receiving multiple organ transplants

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04930289
United States, North Carolina | |
Duke Lung Transplant Clinic | |
Durham, North Carolina, United States, 27710 |
Principal Investigator: | Matthew Hartwig, MD | Duke University |
Responsible Party: | Paragonix Technologies |
ClinicalTrials.gov Identifier: | NCT04930289 |
Other Study ID Numbers: |
PGX-004 |
First Posted: | June 18, 2021 Key Record Dates |
Last Update Posted: | August 10, 2022 |
Last Verified: | August 2022 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Product Manufactured in and Exported from the U.S.: | No |
Cystic Fibrosis Lung Diseases Pulmonary Arterial Hypertension Pulmonary Fibrosis Lung Diseases, Interstitial Fibrosis Emphysema |
Pathologic Processes Pancreatic Diseases Digestive System Diseases Respiratory Tract Diseases Genetic Diseases, Inborn Infant, Newborn, Diseases Hypertension, Pulmonary |